Chengdu Easton Biopharmaceuticals Co. Ltd. has described lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of cancer.
Merck KGaA has divulged proteolysis targeting chimeras (PROTACs) compounds comprising an E3 ubiquitin ligase binding agent coupled to methionine aminopeptidase-2 (MNPEP; MetAP2) targeting moiety via a linker reported to be useful for the treatment of cancer, rheumatoid arthritis, psoriasis, osteoporosis, diabetes, obesity, malaria and benign prostatic hyperplasia, among others.
Gilead Sciences Inc. has identified protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Wuhan LL Science & Technology Development Co. Ltd. has synthesized mannan-binding lectin serine protease 2 (MASP2) inhibitors reported to be useful for the treatment of lupus nephritis and IgA nephropathy, among others.
Adlai Nortye Pharmaceutical Co. Ltd. has disclosed Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Eli Lilly & Co. has described pyrrolidine compounds targeting apolipoprotein(a) (Apo[a]) and acting as lipoprotein(a)-lowering agents reported to be useful for the treatment of cardiovascular disorders.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, neurodegeneration, neuroinflammation, pain and psychiatric disorders.
Vivace Therapeutics Inc. has identified transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, polycystic kidney and hepatic fibrosis.
RSS